The latest total revenue for ALLO is $4.6M as of June 2026. That compares with $-22K in the prior-year period — up 21190.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Allogene Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALLO's total revenue moved from $-22K to $4.6M — a 21190.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allogene Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, ALLO currently prints $4.6M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Allogene Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $4.6M for ALLO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ALLO's total revenue ($4.6M), review year-over-year change from $-22K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.